DNM1L and pulmonary arterial hypertension: Mdivi-1, a Drp1 inhibitor, can improve exercise capacity, right ventricular function, and hemodynamics in experimental pulmonary hypertension by diminishing mitochondrial fission (Marsboom et al., 2012), but further data and application information are needed.